Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 20;7(3):e27063.
doi: 10.2196/27063.

Gaps in Public Awareness About BRCA and Genetic Testing in Prostate Cancer: Social Media Landscape Analysis

Stacy Loeb  1   2 , Philip Massey  3 , Amy E Leader  4 , Sameer Thakker  5 , Emily Falge  5 , Sabina Taneja  5 , Nataliya Byrne  1   2 , Meredith Rose  3 , Matthew Joy  3 , Dawn Walter  1   2 , Matthew S Katz  6 , Risa L Wong  7 , Preethi Selvan  4 , Scott W Keith  8 , Veda N Giri  4   9   10
Affiliations

Gaps in Public Awareness About BRCA and Genetic Testing in Prostate Cancer: Social Media Landscape Analysis

Stacy Loeb et al. JMIR Cancer. .

Abstract

Background: Genetic testing, particularly for BRCA1/2, is increasingly important in prostate cancer (PCa) care, with impact on PCa management and hereditary cancer risk. However, the extent of public awareness and online discourse on social media is unknown, and presents opportunities to identify gaps and enhance population awareness and uptake of advances in PCa precision medicine.

Objective: The objective of this study was to characterize activity and engagement across multiple social media platforms (Twitter, Facebook, and YouTube) regarding BRCA and genetic testing for PCa compared with breast cancer, which has a long history of public awareness, advocacy, and prominent social media presence.

Methods: The Symplur Signals online analytics platform was used to obtain metrics for tweets about (1) #BRCA and #breastcancer, (2) #BRCA and #prostatecancer, (3) #genetictesting and #breastcancer, and (4) #genetictesting and #prostatecancer from 2016 to 2020. We examined the total number of tweets, users, and reach for each hashtag, and performed content analysis for a subset of tweets. Facebook and YouTube were queried using analogous search terms, and engagement metrics were calculated.

Results: During a 5-year period, there were 10,005 tweets for #BRCA and #breastcancer, versus 1008 tweets about #BRCA and #prostatecancer. There were also more tweets about #genetictesting and #breastcancer (n=1748), compared with #genetic testing and #prostatecancer (n=328). Tweets about genetic testing (12,921,954) and BRCA (75,724,795) in breast cancer also had substantially greater reach than those about PCa (1,463,777 and 4,849,905, respectively). Facebook groups and pages regarding PCa and BRCA/genetic testing had fewer average members, new members, and new posts, as well as fewer likes and followers, compared with breast cancer. Facebook videos had more engagement than YouTube videos across both PCa and breast cancer content.

Conclusions: There is substantially less social media engagement about BRCA and genetic testing in PCa compared with breast cancer. This landscape analysis provides insights into strategies for leveraging social media platforms to increase public awareness about PCa germline testing, including use of Facebook to share video content and Twitter for discussions with health professionals.

Keywords: BRCA; breast cancer; genetic testing; infodemiology; prostate cancer; social media.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: SL reports equity in Gilead. VNG reports speaker agreements with Janssen, Invitae, and Ambry Genetics; research funding from the Department of Defense and the Prostate Cancer Foundation; stock ownership in Novopyxis. Others have nothing to disclose.

Figures

Figure 1
Figure 1
Comparison of Tweets, Contributors, and Impressions/Reach for BRCA and Genetic Testing in Breast Cancer versus Prostate Cancer (2016-2020).
See this image and copyright information in PMC

References

    1. Giri Veda N, Knudsen K, Kelly W, Cheng H, Cooney K, Cookson M, Dahut William, Weissman Scott, Soule Howard R, Petrylak Daniel P, Dicker Adam P, AlDubayan Saud H, Toland Amanda E, Pritchard Colin C, Pettaway Curtis A, Daly Mary B, Mohler James L, Parsons J Kellogg, Carroll Peter R, Pilarski Robert, Blanco Amie, Woodson Ashley, Rahm Alanna, Taplin Mary-Ellen, Polascik Thomas J, Helfand Brian T, Hyatt Colette, Morgans Alicia K, Feng Felix, Mullane Michael, Powers Jacqueline, Concepcion Raoul, Lin Daniel W, Wender Richard, Mark James Ryan, Costello Anthony, Burnett Arthur L, Sartor Oliver, Isaacs William B, Xu Jianfeng, Weitzel Jeffrey, Andriole Gerald L, Beltran Himisha, Briganti Alberto, Byrne Lindsey, Calvaresi Anne, Chandrasekar Thenappan, Chen David Y T, Den Robert B, Dobi Albert, Crawford E David, Eastham James, Eggener Scott, Freedman Matthew L, Garnick Marc, Gomella Patrick T, Handley Nathan, Hurwitz Mark D, Izes Joseph, Karnes R Jeffrey, Lallas Costas, Languino Lucia, Loeb Stacy, Lopez Ana Maria, Loughlin Kevin R, Lu-Yao Grace, Malkowicz S Bruce, Mann Mark, Mille Patrick, Miner Martin M, Morgan Todd, Moreno Jose, Mucci Lorelei, Myers Ronald E, Nielsen Sarah M, O'Neil Brock, Pinover Wayne, Pinto Peter, Poage Wendy, Raj Ganesh V, Rebbeck Timothy R, Ryan Charles, Sandler Howard, Schiewer Matthew, Scott E Michael D, Szymaniak Brittany, Tester William, Trabulsi Edouard J, Vapiwala Neha, Yu Evan Y, Zeigler-Johnson Charnita, Gomella Leonard G. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 Aug 20;38(24):2798–2811. doi: 10.1200/JCO.20.00046. - DOI - PMC - PubMed
    1. Cheng Heather H, Sokolova A, Schaeffer E, Small E, Higano C. Germline and Somatic Mutations in Prostate Cancer for the Clinician. J Natl Compr Canc Netw. 2019 May 01;17(5):515–521. doi: 10.6004/jnccn.2019.7307.jnccn19024 - DOI - PubMed
    1. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Prostate Cancer Version 2. 2021. [2021-04-08]. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf . - PubMed
    1. National Comprehensive Cancer Network Clinical Guidelines in Oncology (NCCN Guidelines®): Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 2.2021) 2021. [2021-08-02]. https://www.nccn.org/ - PubMed
    1. Genetics of Prostate Cancer (PDQ®): Health Professional Version. [2021-08-02]. https://www.cancer.gov .